2018 Q4 Form 10-Q Financial Statement
#000114420418057994 Filed on November 07, 2018
Income Statement
| Concept | 2018 Q4 | 2018 Q3 | 2017 Q3 |
|---|---|---|---|
| Revenue | $6.127M | $7.735M | $8.352M |
| YoY Change | -41.15% | -7.39% | 158.5% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $9.200M | $8.300M | $8.100M |
| YoY Change | 8.24% | 2.47% | -40.44% |
| % of Gross Profit | |||
| Research & Development | $43.40M | $41.33M | $41.86M |
| YoY Change | -12.68% | -1.28% | -20.99% |
| % of Gross Profit | |||
| Depreciation & Amortization | $2.000M | $2.100M | $3.500M |
| YoY Change | -4.76% | -40.0% | 59.09% |
| % of Gross Profit | |||
| Operating Expenses | $52.60M | $41.33M | $41.86M |
| YoY Change | -9.62% | -1.28% | -20.99% |
| Operating Profit | -$41.90M | -$41.63M | |
| YoY Change | 0.65% | -34.25% | |
| Interest Expense | -$2.800M | $3.403M | $3.520M |
| YoY Change | -9.68% | -3.32% | 0.26% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $0.00 | -$19.00K | $10.00K |
| YoY Change | -290.0% | -9.09% | |
| Pretax Income | -$49.30M | -$44.60M | -$44.60M |
| YoY Change | -2.95% | 0.0% | -32.73% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$49.33M | -$44.57M | -$44.61M |
| YoY Change | -2.97% | -0.08% | -32.67% |
| Net Earnings / Revenue | -805.19% | -576.21% | -534.09% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$2.568M | -$2.335M | -$3.014M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 382.9M shares | 382.6M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q4 | 2018 Q3 | 2017 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $92.10M | $127.1M | $172.6M |
| YoY Change | -41.45% | -26.36% | -42.52% |
| Cash & Equivalents | $70.15M | $56.50M | $144.7M |
| Short-Term Investments | $22.00M | $70.60M | $68.30M |
| Other Short-Term Assets | $4.321M | $33.40M | $53.40M |
| YoY Change | -7.85% | -37.45% | 0.75% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $119.3M | $160.5M | $226.0M |
| YoY Change | -41.33% | -28.96% | -36.14% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $28.43M | $29.34M | $37.30M |
| YoY Change | -21.01% | -21.33% | -9.02% |
| Goodwill | $51.97M | $52.07M | |
| YoY Change | -2.98% | ||
| Intangibles | $6.541M | $6.754M | |
| YoY Change | -16.92% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $810.0K | $814.0K | $8.900M |
| YoY Change | -6.79% | -90.85% | 2070.73% |
| Total Long-Term Assets | $88.70M | $89.94M | $108.1M |
| YoY Change | -10.57% | -16.8% | 2.27% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $119.3M | $160.5M | $226.0M |
| Total Long-Term Assets | $88.70M | $89.94M | $108.1M |
| Total Assets | $208.0M | $250.5M | $334.1M |
| YoY Change | -31.25% | -25.03% | -27.31% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $9.301M | $6.790M | $5.200M |
| YoY Change | 65.7% | 30.58% | -67.9% |
| Accrued Expenses | $19.55M | $20.96M | $30.20M |
| YoY Change | -33.98% | -30.59% | 15.72% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $45.54M | $46.72M | $68.30M |
| YoY Change | -38.19% | -31.6% | -9.76% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $319.2M | $318.8M | $317.4M |
| YoY Change | 0.44% | 0.44% | 0.44% |
| Other Long-Term Liabilities | $8.687M | $9.112M | $22.50M |
| YoY Change | -15.55% | -59.5% | 555.21% |
| Total Long-Term Liabilities | $8.687M | $9.112M | $339.9M |
| YoY Change | -15.55% | -97.32% | 9798.08% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $45.54M | $46.72M | $68.30M |
| Total Long-Term Liabilities | $8.687M | $9.112M | $339.9M |
| Total Liabilities | $375.9M | $377.2M | $408.2M |
| YoY Change | -7.0% | -7.6% | -0.4% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.299B | -$1.250B | |
| YoY Change | 16.58% | ||
| Common Stock | $3.849M | $3.832M | |
| YoY Change | 18.91% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $2.450M | $2.450M | |
| YoY Change | 0.0% | ||
| Treasury Stock Shares | $455.4K | 455.4K shares | 455.4K shares |
| Shareholders Equity | -$167.9M | -$126.7M | -$74.20M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $208.0M | $250.5M | $334.1M |
| YoY Change | -31.25% | -25.03% | -27.31% |
Cashflow Statement
| Concept | 2018 Q4 | 2018 Q3 | 2017 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$49.33M | -$44.57M | -$44.61M |
| YoY Change | -2.97% | -0.08% | -32.67% |
| Depreciation, Depletion And Amortization | $2.000M | $2.100M | $3.500M |
| YoY Change | -4.76% | -40.0% | 59.09% |
| Cash From Operating Activities | -$45.20M | -$33.60M | -$44.20M |
| YoY Change | 4.15% | -23.98% | -29.05% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$500.0K | -$400.0K | -$1.200M |
| YoY Change | -28.57% | -66.67% | -70.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $48.90M | $8.400M | $43.10M |
| YoY Change | 179.43% | -80.51% | -55.34% |
| Cash From Investing Activities | $48.30M | $8.000M | $42.00M |
| YoY Change | 187.5% | -80.95% | -54.64% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 3.900M | 1.000M | 23.60M |
| YoY Change | -77.59% | -95.76% | 4620.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -45.20M | -33.60M | -44.20M |
| Cash From Investing Activities | 48.30M | 8.000M | 42.00M |
| Cash From Financing Activities | 3.900M | 1.000M | 23.60M |
| Net Change In Cash | 7.000M | -24.60M | 21.40M |
| YoY Change | -176.09% | -214.95% | -30.52% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$45.20M | -$33.60M | -$44.20M |
| Capital Expenditures | -$500.0K | -$400.0K | -$1.200M |
| Free Cash Flow | -$44.70M | -$33.20M | -$43.00M |
| YoY Change | 4.68% | -22.79% | -26.24% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
56496000 | USD |
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-09-30 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
NOVAVAX INC | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001000694 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| dei |
Trading Symbol
TradingSymbol
|
NVAX | ||
| CY2018Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
382850125 | shares |
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
0 | shares | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
106307000 | USD |
| CY2018Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
70612000 | USD |
| CY2017Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
50996000 | USD |
| CY2018Q3 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
17586000 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
28234000 | USD |
| CY2018Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
15847000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
17774000 | USD |
| CY2018Q3 | us-gaap |
Assets Current
AssetsCurrent
|
160541000 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
203311000 | USD |
| CY2018Q3 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
954000 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
890000 | USD |
| CY2018Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
29343000 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
35987000 | USD |
| CY2018Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
6754000 | USD |
| CY2017Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
7873000 | USD |
| CY2018Q3 | us-gaap |
Goodwill
Goodwill
|
52072000 | USD |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
53563000 | USD |
| CY2018Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
814000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
869000 | USD |
| CY2018Q3 | us-gaap |
Assets
Assets
|
250478000 | USD |
| CY2017Q4 | us-gaap |
Assets
Assets
|
302493000 | USD |
| CY2018Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6790000 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5613000 | USD |
| CY2018Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
20963000 | USD |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
29610000 | USD |
| CY2018Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
2031000 | USD |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
5078000 | USD |
| CY2018Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
15365000 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
25625000 | USD |
| CY2018Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1566000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-101732000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
7749000 | USD |
| CY2018Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
46715000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
73675000 | USD |
| CY2018Q3 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
2500000 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
2500000 | USD |
| CY2018Q3 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
318830000 | USD |
| CY2017Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
317763000 | USD |
| CY2018Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
9112000 | USD |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
10287000 | USD |
| CY2018Q3 | us-gaap |
Liabilities
Liabilities
|
377157000 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
404225000 | USD |
| CY2018Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2018Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
3832000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3237000 | USD |
| CY2018Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1132738000 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1020457000 | USD |
| CY2018Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1249773000 | USD |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1114359000 | USD |
| CY2018Q3 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
2450000 | USD |
| CY2017Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
2450000 | USD |
| CY2018Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-11026000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-8617000 | USD |
| CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-126679000 | USD |
| CY2018Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
250478000 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
302493000 | USD |
| CY2018Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | USD |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | USD |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| us-gaap |
Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
|
<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) 2014-09, </div><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers (Topic 606) </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(“ASU 2014-09” or “Topic 606”), and subsequently issued amendments to ASU 2014-09, to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The new revenue standard became effective for the Company on January 1, 2018, and was adopted using the modified retrospective method. The adoption of the new revenue standard as of January 1, 2018 did not materially change the Company’s timing of revenue recognition as the majority of its revenue continues to be recognized under its Grant Agreement with BMGF (see discussion below). Since the Company did not identify any accounting changes that impact its revenue recognition timing, no adjustment to accumulated deficit was required upon adoption.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the new revenue standard for arrangements that are determined within the scope of Topic 606, the Company recognizes revenue following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines the performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company performs research and development under grant, license and clinical development agreements. Payments received in advance of work performed are recorded as deferred revenue.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s current revenue primarily consists of revenue under its Grant Agreement with BMGF (see Note 10). The Company is reimbursed for certain costs that support development activities, including the Company’s global Phase 3 clinical trial in pregnant women in their third trimester, product licensing efforts and efforts to obtain World Health Organization (“WHO”) prequalification of its RSV F Vaccine for infants via maternal immunization (“ResVax™”). The Company’s Grant Agreement does not provide a direct economic benefit to BMGF. Rather, the Company entered into an agreement with BMGF to make a certain amount of ResVax available and accessible at affordable pricing to people in certain low and middle income countries. Based on these circumstances, the Company does not consider BMGF to be a customer and concluded the Grant Agreement is outside the scope of Topic 606. Payments received under the Grant Agreement are considered conditional contributions under the scope of ASC 958-605, </div><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Not-for-Profit Entities – Revenue Recognition,</div></div><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and are recorded as deferred revenue until the period in which such research and development activities are performed and revenue can be recognized.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company analyzed the Grant Agreement with BMGF to determine whether the payments received should be recorded as revenue or as a reduction to research and development expenses. In reaching this determination, management considered a number of factors, including whether the Company is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company’s core operations. Further, management has consistently applied its policy of presenting such amounts as revenue.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2018Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2018Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
|
11000000 | USD |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
44286355 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
36556293 | shares | |
| CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
|
8600000 | USD |
| CY2018Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2018Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
600000000 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
383185993 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
382730563 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
323684820 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
323229390 | shares |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
600000000 | shares |
| CY2018Q3 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
455430 | shares |
| CY2017Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
455430 | shares |
| CY2018Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
75036000 | USD |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
135431000 | USD |
| CY2018Q3 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
70620000 | USD |
| CY2018Q3 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | USD |
| CY2018Q3 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
9000 | USD |
| CY2018Q3 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
70612000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
51013000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
17000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
50996000 | USD |
| nvax |
Available For Sale Securities Number Of Securities Owned
AvailableForSaleSecuritiesNumberOfSecuritiesOwned
|
18 | Number | |
| nvax |
Available For Sale Securities Number Of Securities Owned Unrealized Losses
AvailableForSaleSecuritiesNumberOfSecuritiesOwnedUnrealizedLosses
|
12 | Number | |
| us-gaap |
Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
|
-1491000 | USD | |
| CY2018Q3 | us-gaap |
Revenues
Revenues
|
7735000 | USD |
| CY2017Q3 | us-gaap |
Revenues
Revenues
|
8352000 | USD |
| us-gaap |
Revenues
Revenues
|
28161000 | USD | |
| us-gaap |
Revenues
Revenues
|
20764000 | USD | |
| CY2018Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
41326000 | USD |
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
41862000 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
130382000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
118779000 | USD | |
| CY2018Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8309000 | USD |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8118000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
25185000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
25911000 | USD | |
| CY2018Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
49635000 | USD |
| CY2017Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
49980000 | USD |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
155567000 | USD | |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
144690000 | USD | |
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-41900000 | USD |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-41628000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-127406000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-123926000 | USD | |
| CY2018Q3 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
752000 | USD |
| CY2017Q3 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
531000 | USD |
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
2090000 | USD | |
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
1528000 | USD | |
| CY2018Q3 | us-gaap |
Interest Expense
InterestExpense
|
3403000 | USD |
| CY2017Q3 | us-gaap |
Interest Expense
InterestExpense
|
3520000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
10209000 | USD | |
| us-gaap |
Interest Expense
InterestExpense
|
10549000 | USD | |
| CY2018Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-19000 | USD |
| CY2017Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
10000 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
111000 | USD | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
20000 | USD | |
| CY2017Q3 | us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
3047000 | USD |
| us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
9142000 | USD | |
| us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
9142000 | USD | |
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-44570000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-44607000 | USD |
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.12 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.15 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | ||
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
382315000 | shares |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
296435000 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
365236000 | shares | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
284767000 | shares | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
12199000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
13189000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5445000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
5316000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
6754000 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
7873000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
704000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
586000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
420000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
420000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
420000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
176000 | USD |
| CY2016Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
325000000 | USD |
| CY2016Q1 | us-gaap |
Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
|
10000000 | USD |
| CY2018Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
325000000 | USD |
| CY2017Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
325000000 | USD |
| CY2018Q3 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
6170000 | USD |
| CY2017Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
7237000 | USD |
| CY2018Q3 | us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
3047000 | USD |
| CY2018Q3 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
356000 | USD |
| CY2017Q3 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
356000 | USD |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1067000 | USD | |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1067000 | USD | |
| CY2018Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
3403000 | USD |
| CY2017Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
3403000 | USD |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
10209000 | USD | |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
10209000 | USD | |
| CY2018Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
2.09 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
32300000 | USD |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
300000 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | USD | |
| CY2018Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
23000000 | USD |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y2M12D | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
500000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2100000 | USD | |
| CY2018Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
7735000 | USD |
| CY2017Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
8352000 | USD |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
28161000 | USD | |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
20764000 | USD | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-34000 | USD | |
| CY2018Q3 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
160000 | USD |
| CY2018Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-13000 | USD |
| CY2017Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
0 | USD |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
3510000 | USD | |
| us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
855000 | USD | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
9000 | USD | |
| CY2018Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
147000 | USD |
| CY2017Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1299000 | USD |
| us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
3543000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
98305000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
189817000 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
117172000 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
167069000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-19722000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
19205000 | USD | |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-2409000 | USD | |
| CY2017Q3 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
1299000 | USD |
| us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-2418000 | USD | |
| us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
3544000 | USD | |
| CY2018Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-44423000 | USD |
| CY2017Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-43308000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-137823000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-129417000 | USD | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
6177000 | USD | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
7696000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
55000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-294000 | USD | |
| us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
-4381000 | USD | |
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
1485000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13927000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13057000 | USD | |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
1820000 | USD | |
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-2469000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1693000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-427000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-10497000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
364000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-139559000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-101077000 | USD | |
| us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
37000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
96486000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
46029000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2462000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1133000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
98948000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
47125000 | USD | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-62000 | USD | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
180000 | USD | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-60395000 | USD | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-34567000 | USD | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
179257000 | USD |
| CY2017Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
144690000 | USD |
| nvax |
Proceeds From Issuance Or Sale Of Equity Not Settled
ProceedsFromIssuanceOrSaleOfEquityNotSettled
|
0 | USD | |
| nvax |
Proceeds From Issuance Or Sale Of Equity Not Settled
ProceedsFromIssuanceOrSaleOfEquityNotSettled
|
592000 | USD | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
126000 | USD | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
81000 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
12188000 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
12188000 | USD | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.09 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.83 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.29 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.02 | ||
| CY2018Q3 | nvax |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0 | pure |
| CY2017Q3 | nvax |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0 | pure |
| nvax |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0 | pure | |
| nvax |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0 | pure | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
18750 | shares |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
18750 | shares | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
4.99 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
4.99 | ||
| CY2018Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4431000 | USD |
| CY2017Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4331000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13927000 | USD | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13057000 | USD | |
| CY2017 | us-gaap |
Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
|
200000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-135414000 | USD | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-132927000 | USD | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1 – Organization</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiary, Novavax AB, the “Company”) is a late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s vaccine candidates, including ResVax<div style="vertical-align: super;font-size: smaller;display:inline;">TM</div> and NanoFlu<div style="vertical-align: super;font-size: smaller;display:inline;">TM</div>, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and that may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. The Company’s product pipeline targets a variety of infectious diseases.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2018Q3 | nvax |
Cash Cash Equivalents Marketable Securities Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsMarketableSecuritiesRestrictedCashAndRestrictedCashEquivalents
|
145600000 | USD |
| us-gaap |
Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
|
6.81 | ||
| us-gaap |
Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
|
200000 | USD | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0268 | pure |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0286 | pure |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0161 | pure |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0175 | pure |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0226 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0286 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0161 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0234 | pure | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.1364 | pure |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.1490 | pure |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.1146 | pure |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.1410 | pure |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.1364 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.1490 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.8891 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.1410 | pure | |
| CY2018Q3 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.0375 | pure |
| us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | USD | |
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | USD | |
| us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
0 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
0 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
0 | ||
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
0 | shares |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
0 | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-10256000 | USD | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
4991000 | USD |
